SCHEMBL1708403

SCHEMBL1708403

COC(=O)c1cccc(-n2c(C(F)(F)F)nc3cc(OC)ccc32)c1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.44
POLB P06746 1/20 0.44
RAB9A P51151 1/20 0.44
RXRA P19793 1/20 0.42
THRB P10828 1/20 0.41
PLA2G2A P14555 3/20 0.40
ACSS2 Q9NR19 1/20 0.40
CACNA1D Q01668 1/20 0.39
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
HSD17B10 Q99714 1/20 0.39
BRD4 O60885 2/20 0.39
SLC22A12 Q96S37 1/20 0.38
LMNA P02545 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TP53 P04637 1/20 0.38
KIF11 P52732 1/20 0.38
MYC P01106 1/20 0.38
PLK4 O00444 1/20 0.38
DYRK3 O43781 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1707974 0.86 MAPK1 (0.47) ALDH1A1POLBRAB9ASLC22A12LMNA
SCHEMBL1708107 0.79 TSHR (0.46) ALDH1A1POLBRAB9ATHRBCACNA1D
SCHEMBL1708100 0.78 RAB9A (0.51) ALDH1A1POLBRAB9ATHRBPLA2G2A
SCHEMBL15465181 0.76 ALDH1A1 (0.45) ALDH1A1POLBRAB9AACSS2HSD17B10
SCHEMBL649504 0.74 ALDH1A1 (0.41) ALDH1A1POLBRAB9ARXRATHRB
SCHEMBL2095007 0.74 RAB9A (0.41) ALDH1A1POLBRAB9ATHRBTP53
SCHEMBL1708130 0.73 CYP2D6 (0.42) ALDH1A1POLBRAB9A
SCHEMBL1708022 0.73 ALDH1A1 (0.48) ALDH1A1POLBRAB9ATP53MYC
SCHEMBL2091845 0.72 NPC1 (0.44) ALDH1A1POLBRAB9AL3MBTL1TP53
SCHEMBL2092860 0.72 KDR (0.48) POLBRAB9AKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120172351-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-05 US disclosed
EP-2440541-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-04-18 EP disclosed
WO-2010143733-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172351-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF GPR119, INSR, GLP1R ALDH1A1 3930/4885POLB 4829/4885RAB9A 2224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.